Native low-density lipoproteins are priming signals of the NLRP3 inflammasome/interleukin-1β pathway in human adipose tissue and macrophages.
Simon Bissonnette, Valérie Lamantia, Benjamin Ouimet...
https://pubmed.ncbi.nlm.nih.gov/37914804/Actively Recruiting
Led by May Faraj, PDt, PhD · Updated on 2026-10-08
84
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating whether different types of fish oil supplements can better improve metabolic health in adults at high risk of developing type 2 diabetes. The study focuses on how these supplements affect insulin production and response, the quality of particles that carry bad cholesterol, and the health and function of fat tissue. This trial compares two omega-3 fatty acids, EPA and DHA, with a placebo corn oil to see which might be more beneficial. Participants will be randomly assigned to take daily softgel capsules containing either 4 grams of EPA, 4 grams of DHA, or corn oil as a placebo for 12 weeks. Before and after this period, participants will visit the research unit for specialized metabolic tests, including glucose processing, insulin production assessments, and fat tissue biopsies. These visits occur over six sessions, including baseline assessments and follow-up. During the study, participants will keep a daily log of their capsule intake to monitor adherence. Researchers will measure changes in insulin production and sensitivity, LDL particle size, and fat tissue inflammation before and after the intervention. The primary outcome is the change in the disposition index over 12 weeks. The total participation time in the study lasts approximately 18 to 22 weeks, including screening and intervention periods.
CONDITIONS
Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults
J
Justine Fricher, M.Sc.
C
Clinical coordinator and nurse
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
May Faraj, PDt, PhD
Lead Sponsor
Diabetes Canada
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
2 baseline visits one week apart
Duration - 12 weeks
Participants take daily softgel capsules of EPA, DHA, or corn oil placebo for 12 weeks while keeping a daily log of capsule intake.
6 visits including before and after intervention assessments
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Simon Bissonnette, Valérie Lamantia, Benjamin Ouimet...
https://pubmed.ncbi.nlm.nih.gov/37914804/M Faraj, L Messier, J P Bastard...
https://pubmed.ncbi.nlm.nih.gov/16752182/Valérie Lamantia, Simon Bissonnette, Myriam Beaudry...
https://pubmed.ncbi.nlm.nih.gov/39511203/Tom G Richardson, Qin Wang, Eleanor Sanderson...
https://pubmed.ncbi.nlm.nih.gov/34729547/A Onat, G Can, G Hergenç...
https://pubmed.ncbi.nlm.nih.gov/17299378/Karol M Pencina, Michael J Pencina, Line Dufresne...
https://pubmed.ncbi.nlm.nih.gov/36098309/May Faraj, PDt, PhD
Lead Sponsor
Diabetes Canada
Collaborating Sponsor